Neuropsychiatric lupus: a mosaic of clinical presentations by unknown
Kivity et al. BMC Medicine  (2015) 13:43 
DOI 10.1186/s12916-015-0269-8REVIEW Open AccessNeuropsychiatric lupus: a mosaic of clinical
presentations
Shaye Kivity1,2,5†, Nancy Agmon-Levin1,5†, Gisele Zandman-Goddard3,5, Joab Chapman4,5
and Yehuda Shoenfeld1,5,6,7*Abstract
Neuropsychiatric symptoms affect nearly half of the patients with systemic lupus erythematosus; however, the
effect on disease severity, quality of life, and prognosis is tremendous. Symptoms of neuropsychiatric systemic lupus
erythematosus may range from mild diffuse ones, to acute life threatening events. Although the underlying
mechanisms are still largely unraveled, several pathogenic pathways are identified, such as antibody-mediated
neurotoxicity, vasculopathy due to anti-phospholipid antibodies and other mechanisms, and cytokine-induced
neurotoxicity. In the current review, we describe the old and the new regarding epidemiology, pathophysiology,
diagnosis, and management of neuropsychiatric systemic lupus erythematosus. The possible link between
neuropsychiatric symptoms and specific mechanisms may help to facilitate our understanding of the disease in the
future, thus allowing for better treatment strategies.
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Patients with systemic lupus erythematous (SLE) that
suffer from one or more of several neuropsychiatric symp-
toms represent a subcategory termed ‘neuropsychiatric
lupus’ (NPSLE). Cohorts of SLE patients suggest that
nearly half will suffer from NPSLE during their disease
course. The definition of NPSLE is a tough challenge
owing to the broad spectrum of neuropsychiatric symp-
toms that it encompasses, most of which are non-specific
(for example, headache, cognitive dysfunction, etc.). The
most accepted effort, so far, to classify NPSLE was made
by an American College of Rheumatology (ACR) expert-
committee, in 1999 [1]. This committee identified 19
neuropsychiatric conditions, termed ‘case definitions’, in
NPSLE patients, including 12 central nervous system
(CNS) and 7 peripheral nervous system ones (Box 1). It
should be noted that a few population-based studies,
aimed at validating these ACR-NPSLE case definitions,
did not find them to be effective in differentiating NPSLE
patients from those with neuropsychiatric manifestations* Correspondence: shoenfel@post.tau.ac.il
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unless otherwise stated.not associated with SLE [2]. Being a unique and complex
disease, in terms of diagnoses, management, and mechan-
ism, NPSLE merits a separate discussion. The purpose of
this review is to describe the plethora of data that has ac-
cumulated during the recent years regarding NPSLE man-
ifestations, diagnosis, and therapy.
Review
Epidemiology
The prevalence of SLE varies among populations and is
approximately 50 in 100,000 [3]. However, the estimate
of NPSLE is challenging owing to variations in study de-
signs (prospective or retrospective), follow-up periods,
the uniformity of case definitions, and disease age popu-
lation evaluated (pediatric vs. adult). To overcome this
obstacle, the 1999 ACR-NPSLE case definitions have
been widely used; however, despite this, estimates of the
prevalence of NPSLE has still ranged considerably [4].
Unterman et al. [5] performed a meta-analysis of studies
assessing NPSLE prevalence. According to 10 high-quality
prospective studies, which included 2,049 SLE patients,
the prevalence of NPSLE manifestations among them was
56%. Among these approximately 90% were pure CNS
manifestations. The most frequent NPSLE manifestations
were headache (28.3%), mood disorders (20.7%), cognitivehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
























Case definitions are based on the 1999 American College of
Rheumatology recommendations in neuropsychiatric lupus
syndrome [1].
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disease (8.0%). Epidemiological studies that excluded non-
specific, minor CNS-symptoms, such as mild cognitive
dysfunction, headache, mild depression, and anxiety, dem-
onstrated a lower prevalence of NPSLE. Thus, one may
suggest a new approach to defining NPSLE manifesta-
tions. This approach will address major manifestations
that may serve as criteria and minor ones that are closely
related to SLE but are less specific (for example, head
ache, anxiety, mild memory loss, etc.).
The complex pathophysiology of NPSLE
The development of NPSLE in a specific individual de-
pends on genetic, environmental, and hormonal factors.
Despite decades of research our understanding of NPSLE
remains limited; however, several pathogenic pathwayswere identified and linked to specific clinical manifesta-
tions such as antibody-mediated neurotoxicity, vasculopa-
thy due to anti-phospholipid (aPL) antibodies and other
mechanisms, cytokine-induced neurotoxicity, and loss of
neuroplasticity (Figure 1).
Vasculopathy
While only a minority of NPSLE patients have evidence
of frank vasculitis on imaging or histopathology, a small
vessel thrombotic-vasculopathy has been the predomin-
ant histopathological abnormality in brains of NPSLE
patients at autopsy [6]. This small vessel vasculopathy is
usually non-inflammatory, and its correlation with clin-
ical manifestations is not clear do date. It is presumed
that the vascular damage to the CNS in NPSLE is due to
anti-phospholipid syndrome-related vasculopathy or pe-
netration of other autoantibodies through a damaged
blood brain barrier (BBB), immune complex and com-
plement activation, cardiac emboli caused by Libman-
Zachs endocarditis, and other valvular abnormalities,
vasculitis, or accelerated atherosclerosis.
Autoantibodies
The fact that numerous autoantibodies are detected in
SLE patients, and particularly in NPSLE, as well as the
association between specific autoantibodies and certain
manifestations suggest that their presence is linked dir-
ectly to pathogenesis [5,7,8]. More than 20 autoanti-
bodies have been linked to NPSLE [9].The identification
of pathogenic autoantibodies may serve as a possible
drug target in the future. A few are discussed below.
Anti-ribosomal-P antibodies
The presence of anti-ribosomal-P antibodies in NPSLE
patients was first brought up by Bonfa et al. [10] and
later in numerous cohorts of NPSLE patients [11]. Never-
theless, other reports have failed to confirm this rela-
tionship [12]. A recent meta-analysis suggested that
anti-ribosomal-P antibodies are specifically related to
psychosis in NPSLE [10]. Several studies demonstrated
the ability of anti-ribosomal-P antibodies to bind neuronal
antigens, penetrate neuronal cells, and inhibit protein syn-
thesis [13-15]. Several autoantigens are suspected to in-
teract with anti-ribosomal-P antibodies; however, these
interactions are yet to be confirmed. Recently, it was dem-
onstrated that anti-ribosomal-P may interact with neur-
onal surface-P antigen on the surface of hippocampal
neurons, leading to neuronal apoptosis [16]. In this animal
study, intravenous injected anti-ribosomal P was able to
reach the hippocampus and cause memory impairment
when the BBB was breached [16]. We recently demon-
strated the binding to and penetration of anti-ribosomal-P
antibodies into rat hippocampal and human neuronal cells
[Kivity et al. submitted for publication]. Furthermore, in
Figure 1 Proposed pathogenesis of neuropsychiatric lupus. Auto-antibodies enter the brain causing neuronal damage, including impaired
neuroplasticity and synaptic transition. In order to reach the brain, the blood–brain barrier must be transiently breached by external (for example,
infection) or internal (for example, metabolic derangement, cytokines) triggers. Vascular injury can be antibody mediated by aPL antibodies or via
accelerated classical atherosclerosis. aPL, Anti-phospholipid antibodies; BBB, Blood brain barrier; RiboP, Ribosomal-P; NMDAR, NMDA receptor.
The authors are responsible for designing the figure above.
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roplasticity protein termed the growth associated protein-
43. The binding of anti-ribosomal-P antibody to murine
brain tissue was inhibited by the presence of this protein,
thus suggesting that it may serve as an auto-antigen of
anti-ribosomal-P antibodies in mice [Kivity et al. submit-
ted for publication].
The anti-DNA/NR2 antibodies
While the presence of anti-DNA antibodies correlates with
SLE clinical manifestations, especially glumerulonephritis
and disease activity, its relationship to brain disease is less
clear. Diamond et al. [17] demonstrated that anti-DNA can
recognize a specific sequence (‘DWEYS’) contained in the
N-methyl-D-aspartate (NMDA) receptors NR2a and NR2b.
Passive transfer of anti-DNA/NR2 antibodies causes neur-
onal apoptosis. In addition, active immunization with the
DWEYs followed by breaching of the BBB with lipopolysac-
charide caused hippocampal neuron damage coupled with
memory loss [18]. These anti-DNA/NR2 antibodies can be
detected in the serum and cerebrospinal fluid (CSF) of 25
to 50% of SLE patients and some studies have found a cor-
relation between their blood levels and NPSLE symptoms
[17]. Patients with the severe form of diffuse-NPSLE (acute
confusional state) demonstrate exceptionally high levels ofanti-NR2 antibodies in the CSF accompanied by significant
BBB damage [19]. Murine studies demonstrated that at low
concentration, NMDA receptor-specific antibodies alter
neural synaptic transmission, whereas at high concentra-
tion they induce neuronal death, this may explain why cog-
nitive dysfunction is transient in some patients and
permanent in others [20].
Anti-DNA/16–6 idiotype
The 16–6 idiotype (Id) was originally a monoclonal antibody
directed against human single-stranded-DNA. Over the
years, the 16–6 Id has been detected in up to 30% of lupus
patients and was found to correlate with disease activity [21].
The anti-DNA/16–6 Id is related to NPSLE symptoms and
can bind to human brain tissue ex vivo [21]. Intra-cerebro-
ventricular injection of anti-DNA/16–6 Id was found to
cause histological changes in the hippocampus and amygdala
as well as behavioral and cognitive functions in mice [22].
Anti-phospholipid/anticardiolipin
Anti-phospholipid (aPL) autoantibodies are directed
against epitopes of anionic phospholipids or phospholipid-
binding proteins (for example, B2Gp1). These antibodies
are the most studied in NPSLE, yet their pathogenesis
is not clear. Their net effect, however, is activation of
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sis and natural anticoagulants (for example, protein C
and S), endothelial cell activation, complement activa-
tion, platelet activation, and more [23]. SLE patients
with secondary anti-phospholipid syndrome are prone
to focal neurological manifestations such as stroke, trans-
verse myelitis, and chorea, as well as seizures, migraine,
and cognitive impairments [23].
Anti-GABA
A recent study demonstrated high levels of novel auto-
antibodies to GABA (B1 and B2) receptors in sera and
CSF of NPSLE patients [24].
Blood brain barrier (BBB) disruption
In order to enable auto-antibodies to penetrate the brain
and cause their pathogenic effect, the BBB must be brea-
ched. Different environmental factors, such as infection,
stress, and ischemia, mediated by inflammatory cyto-
kines, may damage the BBB in different anatomical sites,
thus further contributing to the variety of neuropsychi-
atric symptoms. Anti-ribosomal-P and anti-NR2 anti-
bodies can induce the production of pro-inflammatory
cytokines, such as interleukin (IL)-6 and IL-8, by mono-
cytes or endothelial cells. These cytokines may cause in-
flammation of the BBB, further allowing the entrance of
auto-antibodies to the brain [25,26]. Recently, it was
suggested that TWEAK/Fn14 signaling has a role in
compromising the integrity of the BBB in lupus [27].
Cytokines
Cytokines, such as IL-2, IL-10, interferon (IFN)-α, and
IFN-γ, are found to be elevated in the serum of NPSLE
patients. Elevation of cytokines in the CSF is also de-
tected in NPSLE, perhaps produced by infiltrating im-
mune cells or local glial cells. The role of cytokines and
chemokines as mediator of disease as well as target for
therapy is yet to be determined [28].
Murine models – a platform for NPSLE research
SLE murine models can be differentiated into genetically
designed strains that develop a spontaneous lupus-like
autoimmune disease or those induced by adjuvant or
other methods in naïve mice. Genetically prone strains
are characterized by varying proportions by autoanti-
body production, circulating immune complexes, com-
plement consumption, and clinical manifestations such
as glomerulonephritis. These strains include the NZB/
NZWF1, MRL/lpr, NZM2410, and BXSB mice [29]. The
most extensively studied strains are the MRL/lpr and
NZB/NZW F1. The MRL/lpr strain develops a progressive
lupus-like disease due to a molecular defect in the FAS
gene, which is expressed in B and T lymphocytes. This
leads to defective apoptosis, thus causing autoimmunity.The most prominent neuropsychiatric manifestation of
the MRL/lpr mouse is depressive-like behavior, which can
be assessed by the force swimming and anhedonia tests at
5 weeks [30]. Anti-depressants, and more interestingly,
immunosuppressants were found to reduce depression-
like behavior as well as the other SLE symptoms of this
model [31]. However, there is less consistency regarding
anxiety and cognitive impairment in the MRL/lpr mice
[29,31]. MRL/lpr mice produce several autoantibodies
(anti-ribosomal, anti-phospholipid, and anti-nucleosome)
and cytokines in the serum or CSF that may correlate with
neuropsychiatric symptoms [31]. Spontaneous brain mor-
phological alterations are also demonstrated in this strain
[32]. A role for the TWEAK/fn4 pathway in the patho-
genesis of neuropsychiatric symptoms was suggested in
MRL/lpr mice [33]. In addition, it is suggested that pat-
terns of serum antibody binding to peptide microarrays
(immune-signaturing) can predict and diagnose neuro-
psychiatric manifestations in MRL/lpr mice [34]. The
NZB/NZWF1 is the F1 hybrid strain of a cross between
New Zealand Black and New Zealand White mice. It is
the first and most studied spontaneous SLE-like mouse
model. This mice strain develops a severe lupus-like
disease manifested at 5 to 6 months by hyperactive B
and T cells, autoantibodies against nuclear antigens, de-
fective clearance of immune complexes, and glomerulo-
nephritis leading to death. A much more limited number
of studies intended to evaluate NPSLE were done in this
strain, especially due to the severity of clinical disease, its
increased risk of developing inherited brain anomalies,
and a relatively late onset disease.
Clinical manifestations; case definitions (1–12)
The most frequent NPSLE manifestations are headaches,
psychiatric disorders (depression and anxiety), and cog-
nitive dysfunction. Neuropsychiatric symptoms can be
among the earliest manifestations of SLE, and some re-
ports suggest up to 40% of neuropsychiatric symptoms ap-
pear during the first year of SLE diagnosis [7]. Caucasian
ethnicity and older age are associated with shorter time to
neuropsychiatric damage according to the LUMINA study
[35]. NPSLE symptoms can be a devastating manifestation
of SLE, and a recent study demonstrated a standard
mortality ratio of 9.5, markedly with acute confessional
syndrome [36]. NPSLE-CNS case definitions are dis-
cussed below:
1. Although headaches were once considered one of
most common manifestations of NPSLE, several
studies, including a meta-analysis, have more
recently concluded that the rate of headaches
among SLE patients was not significantly higher
than it was in the normal population. In addition,
no particular mechanism was found to be
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with general SLE disease activity, treatment, or a
specific autoantibody [37,38]. Therefore, it has
been suggested that headaches should not be
regarded as a major NPSLE symptom unless they
are intractable to treatment.
2. Seizures, generalized or focal, may develop in 10 to
20% of SLE patients [39], and tend to occur early
in its course [40], especially in SLE patients with
African ethnicity [41]. Generalized seizures tend to
relate to disease activity while focal seizures can
occur at any stage of the disease. It is also crucial
to exclude secondary causes for seizures.
3. The incidence of stroke and transient ischemic
attacks is elevated among SLE patients [42].
Cerebrovascular disease in SLE is strongly related
to the presence of aPL antibodies [43], accelerated
atherosclerosis [44], cardio-embolism due to
heart valvular abnormalities, and Libman-Sacks
endocarditis [45].
4. Clinical evidence of demyelination in NPSLE is
reported in approximately 0.3% of cases.
Demyelination is one of the most poorly
understood and studied NPSLE symptoms, and can
be a clinically isolated syndrome, may overlap with
another CNS demyelinating syndrome (for
example, multiple sclerosis (MS)), be related to
drugs, and, in some cases, the diagnosis can be
made only after long follow-up [46]. However, it
should be noted that up to 60% of NPSLE patients
may have oligoclonal bands in their CSF, and
evidence suggesting demyelination on imaging is
not rare [5]. On the other hand, autoantibodies,
such as aPL antibodies, may be detected in patients
with pure MS [47].
5. Transverse myelitis prevalence in SLE is
approximately 1.5%. Several studies link transverse
myelitis-SLE with aPL antibodies [48], thus
suggesting spinal cord necrosis due to thrombosis
as an etiology. In some cases, an overlap with
Devic’s syndrome with the presence of anti-NMO
antibodies is suspected. In others, transverse
myelitis may convert to definite MS.
6. Chorea is the most common movement disorder in
SLE and appears in 2 to 3% of patients [49,50] and
even in a higher percentage in children, while
Parkinsonism, ataxia, and hemiballismus are
relatively rare. Chorea usually presents during the
first years of SLE, and is accompanied by aPL
antibodies in up to 92% of cases [51,52]. It has
been suggested that these antibodies cross the
BBB, bind to neuronal antigens, and induce this
symptom [53]. Standard brain magnetic resonance
imaging (MRI) has failed to demonstrate significantchanges in choreic NPSLE patients [54], while
functional imaging suggested hyperactivity in the
basal ganglia [49].
7. Aseptic meningitis can be a manifestation of active
SLE. Other causes of aseptic meningitis, such as
infections, medication, and malignancy, should be
excluded.
8. Cognitive impairment is highly prevalent among
lupus patients, ranging from 20 to 80% [5,55].
Cognitive impairment does not seem to be directly
attributable to disease activity, disease burden, or
corticosteroid therapy [56].
The distinction between functional and organic
causes is the most difficult in the case of
psychiatric disorders [57].
9. Depression is the most common mood disorder in
NPLSE, and its lifetime prevalence may reach 65%
[58], while mania is much less common. A recent
study concluded that depression in SLE is linked to
several factors of which the usage of high dose
prednisone (20 mg or higher) was found to be the
most significant independent factor, while global
disease activity was not [59]. Other contributing
factors were recent SLE diagnosis, non-Asian
ethnicity, cutaneous disease, and longitudinal myelitis.
These results may further support the notion that, at
least for some patients, SLE related depression is
associated with adverse events of therapy rather than
with disease activity and may encourage clinicians to
reduce prednisone doses or avoid its use [59]. An
association of depression and specific antibodies
directed at ribosomal-P, NMDA receptor, and other
neuronal epitopes have been suggested [9,60].
10. Anxiety disorders are also common and can affect
up to 40% of patients. Higher anxiety and young
age are risk factors for depression [61].
11. Organic psychosis can affect 2 to 11% [62,63] of SLE
patients. In approximately 60% of these, it tends to
be the presenting SLE-symptom [63]. SLE psychosis
usually correlates with SLE activity and responds to
immunosuppressive therapy. The differential
diagnosis is corticosteroid-induced psychosis, and its
prevalence in SLE was not found to be higher than
in other autoimmune diseases [64].
12. Acute confusional state is a diffuse neurological
dysfunction that manifests as a fluctuating level of
consciousness and disorientation and is equivalent
to the term delirium in the DSM-IV. Due to its
rather vague definition, its prevalence is difficult to
estimate, ranging from 0 to 7% [65].
Other CNS manifestations that are not defined as case
definitions include reversible posterior leukoencephalopathy
syndrome, an increasingly recognized condition in SLE that
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seizures, and altered mental states. Typical neuro-imaging
reveals posterior cerebral white-matter hyper-intensities.
Prognosis is excellent with proper blood pressure and
seizure control.
Olfactory impairments
SLE patients, especially those with active disease or CNS
manifestations have been shown to suffer from olfactory
impairments [66]. Mice injected with anti-ribosomal-P
antibodies intra-cerebra-ventricularily exhibit impaired
olfactory function [67], as well as MRI alterations in ol-
factory brain regions [68].
Peripheral nervous system manifestations
Peripheral nervous system manifestations affect approxi-
mately 10 to 15% of NPSLE cases, and seven are consid-
ered in the 1999 ACR-NPSLE case definitions (Box 1).
The majority manifest as peripheral neuropathy [69], which
includes mono or poly-neuropathy, cranial-neuropathy, in-
flammatory demyelinating poly-radiculoneuropathy, and
plexopathy. A recent finding is that 17% of SLE-related
peripheral neuropathies are small-fiber neuropathy [70].
Small-fiber neuropathies can cause severe burning pain by
targeting unmyelinated C fibers and thinly myelinated A
fibers. The diagnosis can be supported by skin biopsy that
demonstrates damage to the dorsal root ganglia and distal
axons. Other peripheral nervous system manifestations
are autonomic disorders and myasthenia gravis.
Diagnosis and imaging of NPSLE
The diagnosis of NPSLE may resemble the assembly of a
puzzle: a clinician should first diagnose SLE, and then
exclude non-SLE inter-current illness, medication side
effects, and psychosocial- or functional-related condi-
tions. It is important to note also that the manifestations
of NPSLE might overlap the neuropsychiatric manifesta-
tions of Sjögren’s syndrome and aPL syndrome as well
as other autoimmune diseases. Autoantibodies are cen-
tral for the diagnosis of SLE; however, note that the
prevalence of anti-nuclear antibodies in healthy subjects
may reach 20% at certain ages [71], and many non-SLE
patients with mild CNS symptoms, such as weakness or
headache, might have weakly positive anti-nuclear anti-
bodies testing. For patients with established SLE, several
autoantibodies were found to correlate with neuropsy-
chiatric symptoms: aPL antibodies with stroke and vas-
cular dementia, seizures, chorea, headache, and transverse
myelitis; anti-ribosomal-P and depression or psychosis;
anti-neuronal with cognitive dysfunction and depression;
anti-ganglioside antibodies with migraine, acute confu-
sional state, depression, and peripheral neuropathy [72];
yet, none of these antibodies can serve as a definite
marker of NPSLE.Cerebrospinal fluid
CSF analysis in NPSLE patients may be innocent, and
thus non-contributory. In some cases, such as vasculitis,
aseptic meningitis, and transverse myelitis, it may have a
high yield in diagnosis. Several reports demonstrated im-
munological markers such as anti-DNA antibodies, oli-
goclonal banding, immune complexes, IL-6, and markers
of B-cell activation in the CSF of NPSLE patients [73-75].
Psychological testing
Neuropsychological testing may help to differentiate be-
tween functional and non-functional disease, but these
tests are prolonged and complicated and, thus, are al-
most never routinely performed. The 1999 ACR-NPSLE
committee proposed a relatively short (1 hour) battery
of neuropsychological tests for use when NPSLE is sus-
pected (Table 1), which is shorter than the 4 to 5 hour
comprehensive batteries used before. This was validated
and found reliable [76].
Biomarkers in NPSLE
In order to better screen and monitor NPSLE treatment,
there is an ongoing search for biomarkers, other than
autoantibodies, cytokines, and chemokines, in this pa-
tient population. Intra-thecal levels of plasminogen acti-
vator inhibitor 1 and MMP-9 were found to correlate with
NPSLE activity [77]. It was recently demonstrated that the
combination of blood levels of several brain-reactive pro-
teins (neutrophil gelatinase-associated lipocalin, S100B,
and S100A8/9) with anti-NR2 and anti-ribosomal-P anti-
body levels is associated with cognitive impairment in
childhood-onset NPSLE patients [78].
Imaging
Several imaging modalities have enhanced our ability to
investigate NPSLE; others appear promising in the near
future and need further research and validation.
Computerized tomography (CT)
CT is used mainly in emergency settings to exclude focal
abnormalities such as infarcts, hemorrhage, and tumors.
Chronic conditions which can be demonstrated are cor-
tical atrophy and calcifications.
Magnetic resonance imaging (MRI)
MRI is widely used in NPSLE because it is sensitive,
relatively available, and can exclude other neurological
conditions. However, more than half of patients diag-
nosed with NPSLE have a normal MRI of the brain [79],
this is much less so as the disease progresses and
worsens. MRI is mostly sensitive to focal findings such
as cerebrovascular disease and myelitis (80 to 90%),
while its sensitivity decreases for white matter lesions,
gray matter lesions, and cerebral atrophy [80]. It should
Table 1 Neuropsychological testing in neuropsychiatric lupus syndrome (NPSLE) - The ACR 1-hour battery proposal
Test Evaluates
Revised Wechsler Adult Intelligence scale Psychomotor speed, concentration, and graphomotor abilities
Digit Symbol Substitution Test Psychomotor speed, concentration, and graphomotor abilities
The Trail Making Test Part B Psychomotor speed, attention, and cognitive sequencing
The Stroop Color and Word Test Complex attention and shifting of sets by naming color print for words
written in different colors
The learning trial and short delay ‘free’ scores from the California Verbal
Learning Test
Learning and recall of verbal material
The immediate and 30-minute delayed-recall measure of the Rey-Osterrieth
Complex Figure Test
Visual learning and memory
The Wechsler Adult Intelligence Scale Auditory working memory
The Controlled Oral Word Association Test (Letter Fluency) and the Animal
Naming Test (Category Fluency)
Letter and category verbal fluency
The Finger Tapping Test Simple fine motor speed
Proposed 1 hour battery of neuropsychological testing in NPSLE [76].
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Other imaging modalities
Single photon emission computed tomography (SPECT)
provides an estimate of regional cerebral blood flow and
neuronal integrity and was thought to be more sensitive
than MRI for the evaluation of NPSLE by some re-
searchers. However, studies were inconsistent. Positron
emission tomography–CT measures radio-labeled oxygen
and glucose uptake by the brain. Several studies demon-
strated an alteration in cerebral metabolism in NPSLE
[81]. However, this modality is expensive, difficult to per-
form, and has not yet been proven to significantly contrib-
ute to an NPSLE work up [33]. A few studies have shown
defective brain activity during activity such as memory
tasks using functional MRI. In a recent study, childhood-
onset NPSLE patients with cognitive impairment, dem-
onstrated differential activation of functional neuronal
networks during functional MRI tasks, suggesting this
modality can serve as an imaging biomarker [80]. Mag-
netic resonance spectroscopy (MRS) is a relatively new
modality that can non-invasively quantify several me-
tabolites in brain tissue (for example, N-acetyl aspar-
tate) [82,83]. Several metabolites have been used to
examine NPSLE, however, these changes are not spe-
cific to SLE and might be present in other progressive
diseases of the brain such as Alzheimer’s disease and
MS [84]. MRS is not currently recommended for NPSLE
patients although, in the future, it may help monitor and
diagnose NPSLE.
Treatment options for neuropsychiatric lupus
Treatment of NPSLE may combine therapy directed at an
underlying mechanism such as autoantibody mediated
damage or a hyper-coagulable state, while controllingsymptoms with anti-epileptic, anti-depressive, anti-
neuropathy, and other medications. Currently, no ran-
domized controlled studies have been done to verify
therapies or protocols for specific NPSLE manifesta-
tions. Hence, treatment regimens are based on expert rec-
ommendations, case studies, and small controlled trials.
NPSLE therapy should be individualized based on sus-
pected mechanisms (for example, the presence of specific
antibodies or evidence of thrombosis), severity of symp-
toms, expected morbidity, time from onset of symptoms,
reversibility, response to prior therapies, and effect on
quality of life. Symptomatic therapy alone may be consid-
ered for mild NPSLE, especially when further damage is
not expected. For instance, depression, headaches, and re-
current seizures do not commonly represent active SLE
disease, but rather associated conditions or sequel of pre-
vious event (for example, post-stroke seizures). In con-
trast, if severe/new onset disease is diagnosed, especially
in the presence of high SLE activity, immunosuppressant
and/or directed therapy are required to control the auto-
immune process and avoid further damage. Evidence ex-
ists for off-label aggressive intervention for acute NPSLE
such as aseptic meningitis, myelitis, neuropathy, and
psychosis. In general, treatment options for these severe
and acute neuro-psychiatric symptoms are similar to those
utilized for other major organ involvement in SLE or for
non-SLE CNS vasculitis. These include non-specific im-
munosuppression, specific immune modulation mainly
targeted at the humoral arm of the immune system, and/
or anti-coagulation. The most studied immunosuppressive
modality is the use of systemic gluco-corticosteroids (GC)
that may lead to a beneficial response in 60 to 75% of pa-
tients. High doses of GC are almost universally utilized,
and for severe signs or symptoms, ‘pulse therapy’ with very
high doses of GC (for example, IV 1 g solomedrol/day
for 3 to 5 days) followed by oral therapy (for example,
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Although emotional instability, mood swings (for example,
depression), disfigurement, and various other adverse
events are common in SLE patients treated with GC, and
may interfere with the appropriate appraisal of disease, it
is still the most effective immediate therapy available.
In many moderate to severe NPSLE presentations,
additional immune suppressants are required to control
the disease and enable GC withdrawal. Cyclophospha-
mide (CYC) is probably the most used immunosuppres-
sant for severe NPSLE. In a controlled clinical trial [85],
the addition of IV CYC to methylprednisolone was su-
perior to therapy with methylprednisolone pulses alone
for 32 patients with acute severe NPSLE (refractory sei-
zures, cranial or peripheral neuropathy, optic neuritis,
transverse myelitis, brainstem disease, and coma). All pa-
tients were treated with prednisone between pulses. Due
to the effects of CYC, ovarian or sperm preservation
should be considered. In another study, 37 out of 60 pa-
tients with NPSLE were treated with low doses of IV CYC
(200 to 400 mg per month). Treated patients had a statis-
tically significant improvement when compared to the
control group that was treated with prednisone and pla-
quenil only [86]. Several reports describe successful use of
azathioprine and mycophenolate mofetil as second line
therapy [87] and for ‘maintenance therapy’ in order to
avoid prolonged exposure to high dose steroids or as a
substitute for prolonged therapy with CYC. For refractory
disease, and particularly NPSLE which is considered to be
induced by autoantibodies, therapy with anti-B cell ther-
apy (rituximab), plasma exchange, or intravenous immu-
noglobulins (IVIG) may be considered.
Anti-B cell therapies
B-lymphocytes play a central role in lupus pathogenesis,
therefore, drugs such as anti-CD20 monoclonal anti-
bodies (for example, Rituximab), which directly affect
several B cell populations, were suggested for refractory
disease. In a recent systematic review, rituximab was
beneficial in 73 to 100% of 38 patients with refractory
NPSLE; however, relapse rates were high [88], suggesting
that repeated therapy with rituximab may be warranted.
The selection and survival of B cells are controlled by a
variety of signals, including those provided by the lon-
gevity factor, B cell activating factor. Belimumab is a
fully human monoclonal antibody directed against B cell
activating factor that has recently been proven to be a
promising therapy for SLE. Note that in both rando-
mized controlled studies with this new biological drug,
patients with active NPSLE were excluded [89]. How-
ever, post hoc analysis performed for both phase III trials
(BLISS-52 and BLISS-76) demonstrated clinical improve-
ments in organ systems with a low prevalence (≤16%) at
baseline, including the CNS [90].Therapies directed at reducing auto-antibodies with
plasmapheresis or therapy directed at specific cytokines
may also be considered. Plasmapheresis, added as an ad-
junct therapy for chorea or myelitis in NPSLE patients
has been found to be effective. In one retrospective study,
plasmapheresis was added to IV CYC and GC and led to a
complete remission in 54% of 10 NPSLE patients [91]. In
recent years, we successfully treated several patients pre-
senting with acute severe NPSLE with plasmapheresis.
The role of IVIG for NPSLE had been studied in a small
number of patients. In one study of 9 NPSLE patients with
mood swings and cognitive disorders, long-term the-
rapy with high dose IVIG was found to be beneficial
and safe [92].
Anti-aggregation/anticoagulation therapy
There is no question that thrombosis plays a major role
in the pathogenesis of NPSLE, especially in patients with
aPL antibodies. This is typically indicated when mani-
festations are focal, and both clinical and radiographic
evaluation support ischemic or thrombotic events [93].
Therefore, the current recommendation is to treat pa-
tients with SLE who are seropositive to aPL antibodies
with anti-aggregants as primary prevention, while the
addition of anticoagulants is usually reserved for second-
ary prevention [94].
Last but not least, management of precipitating factors
is imperative and includes control of hypertension, infec-
tion, metabolic abnormalities, valvular disease, and ad-
verse drug effects [93].
Future studies
Specific anti-IL-6 drugs have been developed in the last
decade and studied extensively in several autoimmune
conditions. NPSLE was linked with high levels of IL-6 as
well as with BBB disruption by the TWEAK/Fn14 path-
way. Hence, therapies directed at these mediators may
be of value also in NPSLE, although clinical studies are
still lacking.
Conclusions
During the last few decades, overwhelming efforts were
made to elucidate the pathophysiology as well as to im-
prove the classification, diagnosis, and management of
NPSLE. This accumulated information has enhanced our
understanding and ability to help patients. However,
several main issues remain to be solved, namely should
diffuse, mild, and non- specific symptoms (for example,
headaches) be considered the same disease as the more
established manifestations of NPSLE? It is highly un-
likely that the same etiologies are responsible for all
NPSLE patients; therefore, better sub-grouping is required
for clinical and research purposes. What is the true role of
auto-antibodies in NPSLE, and how profound is their role
Kivity et al. BMC Medicine  (2015) 13:43 Page 9 of 11in the pathogenesis of these rather devastating manifesta-
tions? The role of new imaging modalities (for example,
MRS and SPECT, etc.) in the diagnosis and follow-up of
NPSLE should be defined. New biomarkers should be
found. We suggest the development of a severity NPSLE
score, based on symptoms, imaging, and laboratory re-
sults. This score will be aimed to guide treatment intensity
and help monitor clinical studies. Future studies of these
urgent questions are needed, especially in the current era
of biological, target therapies, and personalized medicine.
Abbreviations
ACR: American College of Rheumatology; aPL: Anti-phospholipid; BBB:
Blood brain barrier; CNS: Central nervous system; CSF: Cerebrospinal fluid;
CYC: Cyclophosphamide; GC: Gluco-corticosteroids; Id: Idiotype;
IL: Interleukin; IVIG: Intravenous immunoglobulins; MRI: Magnetic resonance
imaging; MRS: Magnetic resonance spectroscopy; MS: Multiple sclerosis;
NMDA: N-methyl-D-aspartate; NPSLE: Neuropsychiatric systemic lupus
erythematous; SLE: Systemic lupus erythematous; SPECT: Single photon
emission computed tomography.
Competing interest
The authors declare that they have no competing interests.
Authors’ contributions
SK, AL, GZG, and YS performed the literature search and manuscript writing
and editing. JC performed manuscript writing and editing. All authors read
and approved the final manuscript.
Author details
1The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center,
Tel-Hashomer 52621, Israel. 2The Dr. Pinchas Borenstein Talpiot Medical
Leadership Program 2013, Sheba Medical Center, Tel-Hashomer 52621, Israel.
3Department of Medicine C, Wolfson Medical Center, 61 Halochamim Street,
POB 63, Holon 58100, Israel. 4Department of Neurology, Sagol Neuroscience
Center, Sheba Medical Center, Tel-Hashomer 52621, Israel. 5Sackler Faculty of
Medicine, Tel-Aviv University, 39040 Tel-Aviv, Israel. 6Incumbent of the Laura
Schwarz-Kipp Chair for Research of Autoimmune Diseases, Tel-Aviv University,
39040 Tel-Aviv, Israel. 7The Zabludovicz Center for Autoimmune Diseases,
The Chaim Sheba Medical Center, Tel-Hashomer 52621, Israel.
Received: 14 August 2014 Accepted: 6 January 2015
References
1. The American College of Rheumatology nomenclature and case definitions
for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599–608.
2. Ainiala H, Hietaharju A, Loukkola J, Peltola J, Korpela M, Metsanoja R, et al.
Validity of the new American College of Rheumatology criteria for
neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis
Rheum. 2001;45:419–23.
3. Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME. The geoepidemiology
of systemic lupus erythematosus. Autoimmun Rev. 2010;9:A277–87.
4. Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D,
Stallworth CL, et al. Neuropsychiatric syndromes in lupus: prevalence using
standardized definitions. Neurology. 2002;58:1214–20.
5. Unterman A, Nolte JE, Boaz M, Abady M, Shoenfeld Y, Zandman-Goddard G.
Neuropsychiatric syndromes in systemic lupus erythematosus: a
meta-analysis. Semin Arthritis Rheum. 2011;41:1–11.
6. Hanly JG, Walsh NM, Sangalang V. Brain pathology in systemic lupus
erythematosus. J Rheumatol. 1992;19:732–41.
7. Leah E. Bone: finding that osteoclasts repel osteoblast activity through
Sema4D reveals novel target for bone-boosting therapies. Nat Rev
Rheumatol. 2011;7:681.
8. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in
systemic lupus erythematosus: more than 100 different antibodies found in
SLE patients. Semin Arthritis Rheum. 2004;34:501–37.9. Zandman-Goddard G, Chapman J, Shoenfeld Y. Autoantibodies involved in
neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis
Rheum. 2007;36:297–315.
10. Sciascia S, Bertolaccini ML, Roccatello D, Khamashta MA, Sanna G.
Autoantibodies involved in neuropsychiatric manifestations associated
with systemic lupus erythematosus: a systematic review. J Neurol.
2014;261:1706–14.
11. Briani C, Lucchetta M, Ghirardello A, Toffanin E, Zampieri S, Ruggero S, et al.
Neurolupus is associated with anti-ribosomal P protein antibodies: an
inception cohort study. J Autoimmun. 2009;32:79–84.
12. Carmona-Fernandes D, Santos MJ, Canhao H, Fonseca JE. Anti-ribosomal P
protein IgG autoantibodies in patients with systemic lupus erythematosus:
diagnostic performance and clinical profile. BMC Med. 2013;11:98.
13. Koren E, Reichlin MW, Koscec M, Fugate RD, Reichlin M. Autoantibodies to
the ribosomal P proteins react with a plasma membrane-related target on
human cells. J Clin Invest. 1992;89:1236–41.
14. Koscec M, Koren E, Wolfson-Reichlin M, Fugate RD, Trieu E, Targoff IN, et al.
Autoantibodies to ribosomal P proteins penetrate into live hepatocytes and
cause cellular dysfunction in culture. J Immunol. 1997;159:2033–41.
15. Stacey DW, Skelly S, Watson T, Elkon K, Weissbach H, Brot N. The inhibition
of protein synthesis by IgG containing anti-ribosome P autoantibodies
from systemic lupus erythematosus patients. Arch Biochem Biophys.
1988;267:398–403.
16. Bravo-Zehnder M, Toledo EM, Segovia-Miranda F, Serrano FG, Benito MJ,
Metz C, et al. Anti-ribosomal P protein autoantibodies from patients with
neuropsychiatric lupus impair memory in mice. Arthritis Rheumatol.
2015;67:204–14.
17. Diamond B, Volpe BT. A model for lupus brain disease. Immunol Rev.
2012;248:56–67.
18. Diamond B, Bloom O, Al Abed Y, Kowal C, Huerta PT, Volpe BT.
Moving towards a cure: blocking pathogenic antibodies in systemic lupus
erythematosus. J Intern Med. 2011;269:36–44.
19. Hirohata S, Arinuma Y, Yanagida T, Yoshio T. Blood–brain barrier damages
and intrathecal synthesis of anti-N-methyl-D-aspartate receptor NR2
antibodies in diffuse psychiatric/neuropsychological syndromes in systemic
lupus erythematosus. Arthritis Res Ther. 2014;16:R77.
20. Faust TW, Chang EH, Kowal C, Berlin R, Gazaryan IG, Bertini E, et al.
Neurotoxic lupus autoantibodies alter brain function through two distinct
mechanisms. Proc Natl Acad Sci U S A. 2010;107:18569–74.
21. Blank M, Shoenfeld Y. The story of the 16/6 idiotype and systemic lupus
erythematosus. Isr Med Assoc J. 2008;10:37–9.
22. Kivity S, Katzav A, Arango MT, Landau-Rabi M, Zafrir Y, Agmon-Levin N, et al.
16/6-idiotype expressing antibodies induce brain inflammation and
cognitive impairment in mice: the mosaic of central nervous system
involvement in lupus. BMC Med. 2013;11:90.
23. Meroni PL. Pathogenesis of the antiphospholipid syndrome: an
additional example of the mosaic of autoimmunity. J Autoimmun.
2008;30:99–9103.
24. Tsuchiya H, Haga S, Takahashi Y, Kano T, Ishizaka Y, Mimori A.
Identification of novel autoantibodies to GABA(B) receptors in patients
with neuropsychiatric systemic lupus erythematosus. Rheumatology
(Oxford). 2014;53:1219–28.
25. Toubi E, Shoenfeld Y. Clinical and biological aspects of anti-P-ribosomal
protein autoantibodies. Autoimmun Rev. 2007;6:119–25.
26. Yoshio T, Okamoto H, Hirohata S, Minota S. IgG anti-NR2 glutamate receptor
autoantibodies from patients with systemic lupus erythematosus activate
endothelial cells. Arthritis Rheum. 2013;65:457–63.
27. Stock AD, Wen J, Putterman C. Neuropsychiatric lupus, the blood brain
barrier, and the TWEAK/Fn14 pathway. Front Immunol. 2013;4:484.
28. Rhiannon JJ. Systemic lupus erythematosus involving the nervous system:
presentation, pathogenesis, and management. Clin Rev Allergy Immunol.
2008;34:356–60.
29. Jeltsch-David H, Muller S. Neuropsychiatric systemic lupus erythematosus
and cognitive dysfunction: the MRL-lpr mouse strain as a model.
Autoimmun Rev. 2014;13:963–73.
30. Gao H-X, Sanders E, Tieng AT, Putterman C. Sex and autoantibody titers
determine the development of neuropsychiatric manifestations in lupus-
prone mice. J Neuroimmunol. 2010;229:112–22.
31. Gulinello M, Putterman C. The MRL/lpr mouse strain as a model for
neuropsychiatric systemic lupus erythematosus. J Biomed Biotechnol.
2011;2011:207504.
Kivity et al. BMC Medicine  (2015) 13:43 Page 10 of 1132. Sled JG, Spring S, van Eede M, Lerch JP, Ullal S, Sakic B. Time course and
nature of brain atrophy in the MRL mouse model of central nervous system
lupus. Arthritis Rheum. 2009;60:1764–74.
33. Zardi EM, Taccone A, Marigliano B, Margiotta DPE, Afeltra A.
Neuropsychiatric systemic lupus erythematosus: tools for the diagnosis.
Autoimmun Rev. 2014;13:831–9.
34. Williams S, Stafford P, Hoffman SA. Diagnosis and early detection of
CNS-SLE in MRL/lpr mice using peptide microarrays. BMC Immunol.
2014;15:23.
35. Gonzalez LA, Pons-Estel GJ, Zhang J, Vila LM, Reveille JD, Alarcon GS. Time
to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic
lupus cohort. Lupus. 2009;18:822–30.
36. Zirkzee EJM, Huizinga TWJ, Bollen ELEM, van Buchem MA, Middelkoop HAM,
van der Wee NJA, et al. Mortality in neuropsychiatric systemic lupus
erythematosus (NPSLE). Lupus. 2014;23:31–8.
37. Hanly JG, Urowitz MB, O’Keeffe AG, Gordon C, Bae S-C, Sanchez-Guerrero J,
et al. Headache in systemic lupus erythematosus: results from a prospective,
international inception cohort study. Arthritis Rheum. 2013;65:2887–97.
38. Mitsikostas DD, Sfikakis PP, Goadsby PJ. A meta-analysis for headache in
systemic lupus erythematosus: the evidence and the myth. Brain.
2004;127:1200–9.
39. Gonzalez-Duarte A, Cantu-Brito CG, Ruano-Calderon L, Garcia-Ramos G.
Clinical description of seizures in patients with systemic lupus erythematosus.
Eur Neurol. 2008;59:320–3.
40. Andrade RM, Alarcon GS, Gonzalez LA, Fernandez M, Apte M, Vila LM, et al.
Seizures in patients with systemic lupus erythematosus: data from LUMINA,
a multiethnic cohort (LUMINA LIV). Ann Rheum Dis. 2008;67:829–34.
41. Hanly JG, Urowitz MB, Su L, Gordon C, Bae S-C, Sanchez-Guerrero J, et al.
Seizure disorders in systemic lupus erythematosus results from an
international, prospective, inception cohort study. Ann Rheum Dis.
2012;71:1502–9.
42. Timlin H, Petri M. Transient ischemic attack and stroke in systemic lupus
erythematosus. Lupus. 2013;22:1251–8.
43. Petri M, Orbai A-M, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al.
Derivation and validation of the Systemic Lupus International Collaborating
Clinics classification criteria for systemic lupus erythematosus. Arthritis
Rheum. 2012;64:2677–86.
44. Matsuura E, Hughes GRV, Khamashta MA. Oxidation of LDL and its clinical
implication. Autoimmun Rev. 2008;7:558–66.
45. Roldan CA, Gelgand EA, Qualls CR, Sibbitt WL. Valvular heart disease as a
cause of cerebrovascular disease in patients with systemic lupus
erythematosus. Am J Cardiol. 2005;95:1441–7.
46. Magro Checa C, Cohen D, Bollen ELEM, van Buchem MA, Huizinga TWJ,
Steup-Beekman GM. Demyelinating disease in SLE: is it multiple sclerosis or
lupus? Best Pract Res Clin Rheumatol. 2013;27:405–24.
47. Uthman I, Noureldine MH, Berjawi A, Skaf M, Haydar AA, Merashli M, et al.
Hughes syndrome and multiple sclerosis. Lupus. 2014;24:115–21.
48. Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ. Transverse myelopathy in
systemic lupus erythematosus: an analysis of 14 cases and review of the
literature. Ann Rheum Dis. 2000;59:120–4.
49. Baizabal-Carvallo JF, Bonnet C, Jankovic J. Movement disorders in systemic
lupus erythematosus and the antiphospholipid syndrome. J Neural Transm.
2013;120:1579–89.
50. Joseph FG, Lammie GA, Scolding NJ. CNS lupus: a study of 41 patients.
Neurology. 2007;69:644–54.
51. Avcin T, Benseler SM, Tyrrell PN, Cucnik S, Silverman ED. A followup study of
antiphospholipid antibodies and associated neuropsychiatric manifestations
in 137 children with systemic lupus erythematosus. Arthritis Rheum.
2008;59:206–13.
52. Cervera R, Asherson RA, Font J, Tikly M, Pallares L, Chamorro A, et al. Chorea
in the antiphospholipid syndrome. Clinical, radiologic, and immunologic
characteristics of 50 patients from our clinics and the recent literature.
Medicine (Baltimore). 1997;76:203–12.
53. Dale RC, Yin K, Ding A, Merheb V, Varadkhar S, McKay D, et al. Antibody
binding to neuronal surface in movement disorders associated with lupus
and antiphospholipid antibodies. Dev Med Child Neurol. 2011;53:522–8.
54. Galanaud D, Dormont D, Marsault C, Wechsler B, Piette JC. Brain MRI in
patients with past lupus-associated chorea. Stroke. 2000;31:3079–83.
55. Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A. The prevalence of
neuropsychiatric syndromes in systemic lupus erythematosus. Neurology.
2001;57:496–500.56. Hanly JG, Fisk JD, Sherwood G, Eastwood B. Clinical course of cognitive
dysfunction in systemic lupus erythematosus. J Rheumatol. 1994;21:1825–31.
57. van Exel E, Jacobs J, Korswagen LA, Voskuyl AE, Stek M, Dekker J, et al.
Depression in systemic lupus erythematosus, dependent on or independent
of severity of disease. Lupus. 2013;22:1462–9.
58. Bachen EA, Chesney MA, Criswell LA. Prevalence of mood and anxiety
disorders in women with systemic lupus erythematosus. Arthritis Rheum.
2009;61:822–9.
59. Huang X, Magder LS, Petri M. Predictors of incident depression in systemic
lupus erythematosus. J Rheumatol. 2014;41:1823–33.
60. Lapteva L, Nowak M, Yarboro CH, Takada K, Roebuck-Spencer T, Weickert T,
et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction,
and depression in systemic lupus erythematosus. Arthritis Rheum.
2006;54:2505–14. and reference.
61. Maneeton B, Maneeton N, Louthrenoo W. Prevalence and predictors of
depression in patients with systemic lupus erythematosus: a cross-sectional
study. Neuropsychiatr Dis Treat. 2013;9:799–804.
62. Appenzeller S, Cendes F, Costallat LT. Acute psychosis in systemic lupus
erythematosus. Rheumatol Int. 2008;28:237–43.
63. Pego-Reigosa JM, Isenberg DA. Psychosis due to systemic lupus
erythematosus: characteristics and long-term outcome of this rare
manifestation of the disease. Rheumatology (Oxford). 2008;47:1498–502.
64. Sirois F. Steroid psychosis: a review. Gen Hosp Psychiatry. 2003;25:27–33.
65. Kampylafka EI, Alexopoulos H, Kosmidis ML, Panagiotakos DB,
Vlachoyiannopoulos PG, Dalakas MC, et al. Incidence and prevalence of
major central nervous system involvement in systemic lupus erythematosus:
a 3-year prospective study of 370 patients. PLoS One. 2013;8:e55843.
66. Shoenfeld N, Agmon-Levin N, Flitman-Katzevman I, Paran D, Katz BS, Kivity
S, et al. The sense of smell in systemic lupus erythematosus. Arthritis Rheum.
2009;60:1484–7.
67. Katzav A, Ben-Ziv T, Chapman J, Blank M, Reichlin M, Shoenfeld Y. Anti-P
ribosomal antibodies induce defect in smell capability in a model of
CNS-SLE (depression). J Autoimmun. 2008;31:393–8.
68. Kivity S, Tsarfaty G, Agmon-Levin N, Blank M, Manor D, Konen E, et al.
Abnormal olfactory function demonstrated by manganese-enhanced MRI
in mice with experimental neuropsychiatric lupus. Ann N Y Acad Sci.
2010;1193:70–7.
69. Florica B, Aghdassi E, Su J, Gladman DD, Urowitz MB, Fortin PR. Peripheral
neuropathy in patients with systemic lupus erythematosus. Semin Arthritis
Rheum. 2011;41:203–11.
70. Oomatia A, Fang H, Petri M, Birnbaum J. Peripheral neuropathies in systemic
lupus erythematosus: clinical features, disease associations, and
immunologic characteristics evaluated over a twenty-five-year study period.
Arthritis Rheumatol. 2014;66:1000–9.
71. Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, et al.
International recommendations for the assessment of autoantibodies to cellular
antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014;73:17–23.
72. Galeazzi M, Annunziata P, Sebastiani GD, Bellisai F, Campanella V, Ferrara GB,
et al. Anti-ganglioside antibodies in a large cohort of European patients
with systemic lupus erythematosus: clinical, serological, and HLA class II
gene associations: European Concerted Action on the Immunogenetics of
SLE. J Rheumatol. 2000;27:135–41.
73. McLean BN, Miller D, Thompson EJ. Oligoclonal banding of IgG in CSF,
blood–brain barrier function, and MRI findings in patients with sarcoidosis,
systemic lupus erythematosus, and Behcet’s disease involving the nervous
system. J Neurol Neurosurg Psychiatry. 1995;58:548–54.
74. Fragoso-Loyo H, Atisha-Fregoso Y, Llorente L, Sanchez-Guerrero J.
Inflammatory profile in cerebrospinal fluid of patients with headache as
a manifestation of neuropsychiatric systemic lupus erythematosus.
Rheumatology (Oxford). 2013;52:2218–22.
75. Lu XY, Zhu CQ, Qian J, Chen XX, Ye S, Gu YY. Intrathecal cytokine and
chemokine profiling in neuropsychiatric lupus or lupus complicated with
central nervous system infection. Lupus. 2010;19:689–95.
76. Kozora E, Ellison MC, West S. Reliability and validity of the proposed
American College of Rheumatology neuropsychological battery for systemic
lupus erythematosus. Arthritis Rheum. 2004;51:810–8.
77. Jeltsch-David H, Muller S. Neuropsychiatric systemic lupus erythematosus:
pathogenesis and biomarkers. Nat Rev Neurol. 2014;10:579–96.
78. Brunner HI, Klein-Gitelman MS, Zelko F, Beebe DW, Foell D, Lee J, et al.
Blood-based candidate biomarkers of the presence of neuropsychiatric
systemic lupus erythematosus in children. Lupus Sci Med. 2014;1:e000038.
Kivity et al. BMC Medicine  (2015) 13:43 Page 11 of 1179. Toledano P, Sarbu N, Espinosa G, Bargallo N, Cervera R. Neuropsychiatric
systemic lupus erythematosus: magnetic resonance imaging findings and
correlation with clinical and immunological features. Autoimmun Rev.
2013;12:1166–70.
80. Jeong HW, Her M, Bae JS, Kim SK, Lee SW, Kim HK, et al. Brain MRI in
neuropsychiatric lupus: associations with the 1999 ACR case definitions.
Rheumatol Int. 2014. [Ahead of print.]
81. Weiner SM, Otte A, Schumacher M, Klein R, Gutfleisch J, Brink I, et al.
Diagnosis and monitoring of central nervous system involvement in
systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET.
Ann Rheum Dis. 2000;59:377–85.
82. Appenzeller S, Costallat LTL, Li LM, Cendes F. Magnetic resonance
spectroscopy in the evaluation of central nervous system manifestations of
systemic lupus erythematosus. Arthritis Rheum. 2006;55:807–11.
83. Gal Y, Twig G, Mozes O, Greenberg G, Hoffmann C, Shoenfeld Y. Central
nervous system involvement in systemic lupus erythematosus: an imaging
challenge. Isr Med Assoc J. 2013;15:382–6.
84. Peterson PL, Axford JS, Isenberg D. Imaging in CNS lupus. Best Pract Res
Clin Rheumatol. 2005;19:727–39.
85. Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, Jara LJ, Fraga-Mouret A,
Miranda-Limon JM, et al. Controlled clinical trial of IV cyclophosphamide
versus IV methylprednisolone in severe neurological manifestations in
systemic lupus erythematosus. Ann Rheum Dis. 2005;64:620–5.
86. Stojanovich L, Stojanovich R, Kostich V, Dzjolich E. Neuropsychiatric lupus
favourable response to low dose i.v. cyclophosphamide and prednisolone
(pilot study). Lupus. 2003;12:3–7.
87. Tomietto P, D’Agostini S, Annese V, De Vita S, Ferraccioli G. Mycophenolate
mofetil and intravenous dexamethasone in the treatment of persistent
lupus myelitis. J Rheumatol. 2007;34:588–91.
88. Cobo-Ibanez T, Loza-Santamaria E, Pego-Reigosa JM, Marques AO,
Rua-Figueroa I, Fernandez-Nebro A, et al. Efficacy and safety of rituximab
in the treatment of non-renal systemic lupus erythematosus: a systematic
review. Semin Arthritis Rheum. 2014;44:175–85.
89. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al.
Efficacy and safety of belimumab in patients with active systemic lupus
erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet.
2011;377:721–31.
90. Manzi S, Sanchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al.
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on
disease activity across multiple organ domains in patients with systemic
lupus erythematosus: combined results from two phase III trials. Ann Rheum
Dis. 2012;71:1833–8.
91. Bartolucci P, Brechignac S, Cohen P, Le Guern V, Guillevin L. Adjunctive
plasma exchanges to treat neuropsychiatric lupus: a retrospective study on
10 patients. Lupus. 2007;16:817–22.
92. Zandman-Goddard G, Krauthammer A, Levy Y, Langevitz P, Shoenfeld Y.
Long-term therapy with intravenous immunoglobulin is beneficial in
patients with autoimmune diseases. Clin Rev Allergy Immunol. 2012;42:247–55.
93. Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and management of
neuropsychiatric SLE manifestations. Nat Rev Rheumatol. 2010;6:358–67.
94. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary
thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis
Rheum. 2007;57:1487–95.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
